Superworth

Gyre Therapeutics free cash flow GYRE

Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$15.7M
Latest quarter, Q2 FY26
−$17M
−1069% on a year earlier
Fiscal year 2025
−$259K

Gyre Therapeutics' free cash flow was −$15.7M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$17M, down 1069% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$259Kn/a
FY2024−$6M−134%
FY2023$17.4Mn/a
FY2021n/an/a
FY2019−$43.7Mn/a
FY2018−$28.9Mn/a
FY2017−$20Mn/a
FY2016−$18.9Mn/a
FY2015n/an/a
FY2014n/an/a
FY2013−$40.7Mn/a
FY2012−$64.6Mn/a
FY2011−$85.1Mn/a
FY2010n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$17M−1069%−$15.7M
Q1 FY26$3Mn/a$3M
Q4 FY25−$5.8Mn/a−$259K
Q3 FY25$4M+288%$2.8M
Q2 FY25$1.8Mn/a−$158K
Q1 FY25−$251K−109%−$8.9M
Q4 FY24−$2.7M−360%−$6M
Q3 FY24$1M−82%−$2.2M
Q2 FY24−$6.9M−438%$2.3M
Q1 FY24$2.7M−69%$11.4M
Q4 FY23$1Mn/a$17.4M
Q3 FY23$5.6Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Gyre Therapeutics' size, closest first, today.

CompanyFree cash flow yield
GYREGyre Therapeutics−2.4%
CRMDCorMedixn/m
ZVRAZevra Therapeutics5.6%
IRWDIronwood Pharmaceuticalsn/m
COLLCollegium Pharmaceuticaln/m
PBYIPuma Biotechnology7.2%
ABUSArbutus Biopharman/m
ARVNArvinas−43.7%
AMPHAmphastar Pharmaceuticals14.3%
OMEROmeros−5.7%
PCRXPacira BioSciences12.4%
Peer median6.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Gyre Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.